Phase 2 Lymphoma Trial, Recruiting NCT06764017 Sponsor: First Affiliated Hospital of Ningbo University Condition: Lymphoma
Back to Lymphoma

Phase 2 Lymphoma Trial, Recruiting

NCT06764017
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 70 years or older
  • People whose overall physical functioning falls within a specific range (called an ECOG score of 0–3, which covers anything from fully active to limited in self-care — confirm with trial site)
  • People assessed as "unfit" or "frail" on a simplified geriatric (older adult) health assessment
  • People with a confirmed diagnosis of a specific type of blood cancer called CD20-positive diffuse large B-cell lymphoma (DLBCL), based on a tissue biopsy, according to 2016 World Health Organization criteria — excluding one particular subtype called "transformed type 2 DLBCL"
  • People whose cancer cells test positive for two specific proteins called MYC and BCL2, at levels confirmed by laboratory tissue testing
  • People who have not previously received any treatment for this condition
  • People whose heart, liver, and kidney function results fall within the acceptable ranges set by the trial
  • People who have at least one area of cancer that can be measured on a scan
  • People who are either unable to tolerate standard chemotherapy (called CHOP regimen) or who do not wish to receive chemotherapy
  • People who are able to understand and freely sign a consent form agreeing to take part

Who may not be able to join:

  • People whose cancer has spread to the central nervous system (brain or spinal cord) at the time of diagnosis
  • People with a known HIV infection
  • People who are pregnant or breastfeeding
  • People who have another cancer that currently requires treatment
  • People with an active infection that cannot be controlled
  • People with active hepatitis B whose viral levels remain above a certain threshold despite antiviral treatment
  • People who are unable to understand the study requirements, follow the study procedures, or sign the consent form

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 15968985233

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
First Affiliated Hospital of Ningbo University
Registry
ClinicalTrials.gov
Start date
1 February 2025
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

the complete remission rate (CRR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov